Multicenter Clinical Trials Made Easy

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a 13-member clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP) that offers simplified solutions for multicenter clinical trials. Capitalizing on their scientific and clinical expertise and unique institutional resources, PCCTC members collaborate to design, implement and complete phase I and phase II trials in prostate cancer to rapidly bring scientific discoveries to patients.

Latest News





PCCTC Study Shows Zytiga May Improve Outcomes When Taken Bef (10/14/14)

To address the need for better therapies for men with high-risk localized prostate cancer, Dr. Mary-Ellen Taplin of the Dana-Farber Cancer Institute led a multicenter PCCTC clinical trial to test the hypothesis that intense androgen-deprivation therapy (ADT), a luteinizing hormone-releasing hormone agonist (LHRHa) combined with abiraterone acetate (Zytiga) before prostatectomy, can improve survival. This comprehensive [...]

RFA: PCCTC Affiliate Clinical Research Sites (07/22/14)

The PCCTC is now accepting applications for its Affiliate Clinical Research Site program. Key Dates RFA Issue date: July 22, 2014 Application deadline: August 22, 2014 Expected membership notification date: September 26, 2014   Overview Consisting of a network of physician-investigators at academic institutions, the Prostate Cancer Clinical Trials Consortium (PCCTC) is the nation’s leading [...]

PCCTC Trial Shows Tasquinimod Prolongs Survival in Metastati (11/22/13)

Survival data from a phase II PCCTC trial of single agent tasquinimod (NCT00560482) further support the development of this novel drug in men with minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Results published online in the journal Clinical Cancer Research demonstrate a long-term survival benefit, measured by progression-free survival (PFS) and overall survival (OS), as [...]

Radium Ra 223 dichloride (Xofigo Injection) FDA Approved for (05/20/13)

On May15, 2013, the U. S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is an alpha-particle emitting radiotherapeutic drug which mimics calcium and forms complexes with [...]